Clinically, the oral covalent LSD1 inhibitor iadademstat, combined with azacitidine, showed encouraging activity in older or unfit AML patients in the ALICE trial, with 2024 data reporting a 52% overall response rate (ORR) and a safety profile dominated by manageable myelosuppression, dysgeusia, and low-grade gastrointestinal events (Salamero et al., 2024). Here, KDM1A is linked to acute myeloid leukemia.